We use cookies to help us improve your browsing experience and understand how people use our website. Our privacy statement explains how we use cookies, and how to change your cookie settings.
OK
Annual report 2017

New results with filgotinib

Primary endpoint achieved in Ph2 psoriatic arthritis and progression towards Ph3 in ulcerative colitis

Read our press release

Welcome to Galapagos

Galapagos is a clinical-stage biotechnology company, specialized in the discovery and development of small molecule medicines with novel modes of action. Our ambition is to become a leading global biotechnology company, focused on the development and commercialization of novel medicines that will improve people's lives. 

Learn more about Galapagos

News

Loading...

All Galapagos news

Events

Loading...

All Galapagos events

Current Openings

Loading...

All Current Openings